Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV real-world study of sofosbuvir + velpatasvir in chronic hepatitis C in Pakistan
IRCT20170614034526N4Phase 4Completed
- Sponsor
- Hilton Pharma
- Start
- Apr 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sofosbuvir and velpatasvir in hepatitis C virus infection, sponsored by Hilton Pharma. Primary endpoint: Sustained virologic response. Started Apr 2018; status: completed.
02
Drugs
sofosbuvirvelpatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on IRCT20170614034526N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170614034526N4.